Background Image
Previous Page  158 / 182 Next Page
Information
Show Menu
Previous Page 158 / 182 Next Page
Page Background

157

http://www.DGS-PraxisLeitlinien.de

Nr.

Nachweis

56

Darwish M, Kirby M, Robertson P, Tracewell W, Jiang JG. Absorption of fentanyl from

fentanyl buccal tablet in cancer patients without oral mucositis: a pilot study. Clin Drug

Invest 2007; 27: 605-611.

57

Darwish M, Tempero K, Kirby M, Thompson J. Pharmacokinetics and dose proportio-

nality of fentanyl effervescent buccal tablets in healthy volunteers. Clin Pharmacokinet

2005; 44: 1279-1286.

58

Davies AN (Hrsg.). Cancer-related breakthrough pain. Oxford: Oxford University Press,

2006.

59

Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G. The management of cancer-

related breakthrough pain: recommendations of a task group of the Science Committee

of the Association for Palliative Medicine of Great Britain and Ireland. European Journal

of Pain 2009; 13(4): 331-338.

60

Davies AN, Sitte T, Elsner F, Reale C, Espinosa J, Brooks D, Fallon M. Consistency of

efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray

compared with immediate-release morphine sulfate in breakthrough cancer pain. J Pain

Symptom Manage 2011; 41(2): 358-366.

61

Davies AN, Vriens J, Kennett A, McTaggart M. An observational study of oncology

patients’ utilisation of breakthrough pain medication. Journal of Pain and Symptom

Management 2008; 35(4): 406-411.

62

Davies AN, Vriens J. Oral transmucosal fentanyl citrate and xerostomia. J. Pain Symptom

Manage 2005; 30(6): 496-497.

63

Davies AN, Zeppetella G, Andersen S, Damkier A, Vejlgaard T, Nauck F, Radbruch L,

Sjolund K-F, Stenberg M, Buchanan A. Multi-centre European study of breakthrough

cancer pain: Pain characteristics and patient perceptions of current and potential ma-

nagement strategies. European Journal of Pain 2011; 15: 756-763.

64

Davies AN. Current thinking in cancer breakthrough pain management. Eur J Palliative

Care 2005; 12 (Suppl.): 4-6.

65

Davies AN. General principles of management. In: Davies AN (Hrsg.), Cancer-related

breakthrough pain. Oxford: Oxford University Press; 2006, 31-42.

66

Davies AN. Introduction. In: Davies AN (Hrsg.), Cancer-related breakthrough pain.

Oxford: Oxford University Press; 2006, 1-11.

67

Davies AN. The assessment and measurement of physical pain. In: Hillier R, Finlay I,

Miles A (Hrsg.), The effective management of cancer pain (2. Aufl., 23-28). London:

Aesculapus Medical Press, 2002.

68

Davis MP. Are there cost benefits to fentanyl for breakthrough pain? J Pain Symptom

Manage. 2012 Sep; 44(3): e1-2.

69

Davis MP. Fentanyl for breakthrough pain: a systematic review. Expert Review of Neuro-

therapeutics 2011; 11(8): 1197-1216.

70

de Oliveira R, dos Reis MP, Prado WA. the effects of early or late neurolytic sympathetic

plexus block on the management of abdominal or pelvic cancer pain. Pain 2004; 110:

400-408.

Literaturverzeichnis